secwatch.observer — SEC 8-K summary
======================================

Issuer:     Shattuck Labs, Inc. (STTK)
CIK:        0001680367
Form:       8-K
Filed at:   2023-05-09T23:59:59+00:00
Accession:  0001680367-23-000033
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Shattuck Labs reports Q1 net loss $20.7M; cash $135.5M; clinical milestones on track
--------------------------------------------------------------------------------

- Net loss $20.7M ($0.49 per share) vs $24.5M ($0.58 per share) in Q1 2022.
- Cash and investments $135.5M at March 31, 2023, expected to fund operations through year-end 2024.
- R&D expenses $16.7M (down from $19.2M); G&A $5.1M (flat YoY).
- Complete Phase 1A monotherapy data for SL-172154 in PROC to be presented at ASCO June 2023.
- Initial Phase 1B combo data (liposomal doxorubicin) expected mid-2023; mirvetuximab combo trial dosed first patients.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1680367/000168036723000033/0001680367-23-000033-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1680367/000168036723000033/sttk-20230509.htm
  HTML page:      https://secwatch.observer/filing/0001680367-23-000033

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer